Research
-
BPC-157 News Update: September 2026
A July FDA advisory vote moved the conversation forward, but it did not change the law or establish that BPC-157 works in people. A new rat study adds evidence, with the same important limit: it was not a human trial.
-
Hims Peptides: What Hims & Hers Plans to Sell
On October 29, 2026, Hims & Hers previewed Peptides+, naming five planned offerings and BPC-157 and TB-500 as future additions.
-
What Is an IND? A Plain-English FDA Guide
An IND is the filing that lets a sponsor begin testing an investigational drug in people. It opens a research path, not a sales or prescription path.
-
FDA Category 2 Bulk Drug Substances: What It Means
Category 2 means FDA has identified significant safety concerns about a nominated compounding ingredient. Here is what the category tells a patient, and why leaving it does not mean approval.
-
Gray Market Peptides: What Johns Hopkins Found
Johns Hopkins says the market for unverified peptide vials is growing much faster than the human evidence. The useful question is what a prescription and a pharmacy change.
-
When Was Rybelsus Approved? September 20, 2019
Rybelsus was approved on September 20, 2019. The FDA letter marked the moment a GLP-1 medicine moved from injection-only treatment into a daily tablet.
-
Forzinity Approval: One Year Later
On September 19, 2025, Forzinity became the first treatment for Barth syndrome through accelerated approval. A year later, that narrow decision still rests on a required confirmatory trial.
-
Is GHK-Cu FDA Approved? No, Its Review Is Pending
GHK-Cu is not FDA-approved. Its compounding review separates non-injectable use from injections, and the next advisory meeting still has no specific date.
-
503B Outsourcing Facility: What the Term Means
A 503B facility can prepare compounded medicines for clinic stock under federal manufacturing rules. Its registration describes the facility, not a review of each medicine.
-
FDA Tentative Approval: What It Means
FDA tentative approval means an application has cleared the scientific review needed for approval, but a legal barrier still prevents U.S. marketing. It is a real milestone, not permission to sell the drug.
-
Semax FDA History: What the July Vote Changed
Semax has never had an FDA-approved U.S. product. A July 2026 advisory vote supported possible 503A listing, but it did not add Semax to the list or approve a drug.
-
Tirzepatide News Update: September 2026
The month's biggest change is narrow but important: Mounjaro gained a cardiovascular-risk indication for certain adults with type 2 diabetes. Here is what else changed—and what did not.
-
503B Bulks List GLP-1: Still a Proposal
FDA proposes leaving three GLP-1 ingredients off the 503B bulks list. Comments closed July 30; patient-specific prescriptions follow separate rules.
-
Novo Nordisk Lilly Lawsuit: What It Doesn't Decide
The fight is about how Zepbound ads frame a head-to-head trial after a higher Wegovy dose reached the market. It is not a court verdict on which medication is better for you.
-
Semaglutide News Update: September 2026
New child-trial results, heart-failure guidance, access changes and a June label update—what each means for a semaglutide prescription.
-
FDA Telehealth Compounded Drugs: 5 Red Flags
FDA says telehealth sites must not present a compounded drug as a generic, a brand equivalent, or an agency-reviewed product. Here is what an honest prescription page should make clear.
-
How to Get Sermorelin Prescribed: Four Steps
Getting a sermorelin prescription starts with a compound-specific medical intake, followed by a real clinician's review. Symptoms and labs can inform the decision, but neither guarantees a prescription.
-
GLP-1 Heart Failure Guidelines Changed in 2026
Europe's 2026 ESC guideline now says semaglutide or tirzepatide should be considered for a narrow group with symptomatic heart failure and obesity. It is an option for a cardiologist to weigh, not a direction to start either drug on your own.
-
How to Choose a Tirzepatide Provider: 7 Checks
Most of the difference between a careful service and a careless one shows up before a vial ever arrives — in who reads your history, who makes the medicine, and whether anyone answers afterwards.
-
Peptide Research 2026: What Three Reviews Found
Three review papers landed within a few weeks of each other this summer. They agree the animal work is real, the human evidence is thin, and that gap is the thing worth understanding.
Page 7 of 8 · 160 articles